Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
MDT — frequently asked questions
Is Medtronic plc overvalued?
In our latest published analysis dated 2026-05-12, MDT looks meaningfully undervalued. The price recorded at analysis is 76,8 USD versus our fair value of 95,9 USD; the high endpoint is presented separately as potential value of 114 USD. That implies roughly 24.8% upside to fair value at that date.
Our latest published report, analyzed 2026-05-12, gives MDT a fair value of 95,9 USD and a potential value of 114 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Medtronic plc's archetype; it is a dated research output, not a live price.
Should I buy MDT now?
Our latest published rating for MDT, analyzed 2026-05-12, is Buy. Medtronic plc looks meaningfully undervalued at the analysis-date price of 76,8 USD versus fair value of 95,9 USD; potential value is 114 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for MDT?
The dedicated bear-case section in our report analyzed 2026-05-12 documents Medtronic plc's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is MDT's rating?
Our latest published rating for MDT, analyzed 2026-05-12, is Buy, with a published moat assessment of 9/10 (Wide). It reflects our fair value of 95,9 USD, the potential value of 114 USD, and the price recorded at analysis (76,8 USD).
Este informe aún no se ha traducido. Actualice en unos minutos una vez que la cola de traducción se ponga al día.
§1 Resumen ejecutivoEN
Respuesta en 30 segundosBuy
Precio frente a valor
Precio
$76.82
Valor razonable
$95.89
Valor potencial
$113.75
A fecha de
Fecha de cotización no registrada
Por qué puede funcionar
Bull: Successful launch and rapid adoption of new therapies reignite mid-single-digit top-line growth, driving operating leverage and margin expansion.
Qué cambiaría nuestra opinión
Pipeline Stagnation: Regulatory and clinical trial setbacks for Cardiovascular and Diabetes pipelines stall product cycles, allowing competitors to permanently seize market share.
Medtronic is a dominant, entrenched player in the global medical devices industry. While near-term growth is sluggish and quarterly earnings are compressed, its immense scale, high switching costs for healthcare providers, and reliable free cash flow easily support a high dividend payout, fitting the classic mature dividend archetype.
Medtronic is a dominant, entrenched player in the global medical devices industry. While near-term growth is sluggish and quarterly earnings are compressed, its immense scale, high switching costs for healthcare providers, and reliable free cash flow easily support a high dividend payout, fitting the classic mature dividend archetype.
Buy. Medtronic's deeply entrenched portfolio and cash generation capabilities are severely undervalued by a market fixated on near-term trailing stagnation.
Descripción general de la empresa
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
§2 Caso bajistaEN
A prolonged period of sluggish top-line growth combined with intense pricing pressure and hospital capital constraints severely compresses operating margins below the 19.5% baseline, threatening Medtronic's reliable free cash flow and forcing a cut to its high dividend payout.
Intense competition and pricing pressure erode gross margins, threatening the dividend growth trajectory and resulting in severe multiple compression.
Cómo puede fallar esta tesis
Pipeline Stagnation
Medium
Regulatory and clinical trial setbacks for Cardiovascular and Diabetes pipelines stall product cycles, allowing competitors to permanently seize market share.
FV impact
-20%
Trigger
12-24 months
Hospital Capital Freeze
Low
Macroeconomic pressures force severe hospital capital constraints and widespread deferral of elective procedures, crushing revenue growth to negative territory.
Señales de alerta temprana a vigilar
Los cinco acontecimientos que debilitarían nuestra tesis de inversión.
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
En línea
Hold
Disparador: In-line results
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
Fallo
Reassess
Disparador: Downside surprise
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
Calidad de los beneficios
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
Ingresos más recientes33,5 mil MCAGR de ingresos +1,9 %
Margen operativo19,5 %4 periodos fiscales
Flujo de caja libre más reciente5185 MFY2025
Deuda neta26,3 mil MFY2025
Desglose de la cuenta de resultadosCómo la escala del negocio se convierte en beneficio declarado.
StockMarketAgent.AI
Ingresos33,5 mil MCoste de ventas−11,6 mil MBeneficio bruto21,9 mil MGastos operativos−15,4 mil MBeneficio operativo6540 MPartidas no operativas e impuestos−1878 MBeneficio neto4662 M
Datos del historial financiero
Ingresos
33.537.000.000
Coste de ventas
11.632.000.000
Beneficio bruto
21.905.000.000
Gastos operativos
15.365.000.000
Beneficio operativo
6.540.000.000
Partidas no operativas e impuestos
-1.878.000.000
Beneficio neto
4.662.000.000
Resumen del balanceCómo se mantienen y financian los activos declarados en el período seleccionado.
StockMarketAgent.AI
Composición de activosFinanciado por
Activos totales91,7 mil MEfectivo2218 MActivos corrientes23,8 mil MPasivos totales43,4 mil MPasivos corrientes12,9 mil MPatrimonio neto48 mil M
Datos del desglose del balance
Activos totales
91.680.000.000
Efectivo
2.218.000.000
Activos corrientes
23.814.000.000
Pasivos totales
43.424.000.000
Pasivos corrientes
12.879.000.000
Patrimonio neto
48.024.000.000
Ingresos y beneficiosCómo la escala del negocio se convierte en beneficio declarado.
Efectivo y deudaLiquidez disponible frente al endeudamiento total.
Generación de efectivoFlujo de caja operativo frente al flujo de caja libre.
RentabilidadEvolución de los márgenes bruto, operativo y neto.
Datos financieros puntuales utilizados en el análisis del 2026-05-12.
Datos del historial financiero
Período
Ingresos
EBITDA
Beneficio neto
Flujo de caja operativo
Flujo de caja libre
Capex
Depreciación y amortización
Compensación basada en acciones
Recompras de acciones
Dividendos pagados
Emisión neta de deuda
Flujo de inversión
Flujo de financiación
Efectivo inicial
Efectivo final
Efectivo e inversiones
Deuda total
Margen operativo
ROIC
WACC
Diferencial ROIC−WACC
2022-04-30
31,7 mil M
8777 M
5039 M
7346 M
5978 M
1368 M
2707 M
359 M
2544 M
3383 M
-1 M
—
—
—
—
3714 M
24,1 mil M
18,6 %
—
5,9 %
—
2023-04-30
31,2 mil M
8697 M
3758 M
6039 M
4580 M
1459 M
2697 M
355 M
645 M
3616 M
-598 M
—
—
—
—
1543 M
24,4 mil M
18,7 %
—
6,2 %
—
2024-04-30
32,4 mil M
8203 M
3676 M
6787 M
5200 M
1587 M
2647 M
393 M
2138 M
3666 M
1073 M
—
—
—
—
1284 M
25 mil M
17,1 %
—
7,3 %
—
2025-04-30
33,5 mil M
9218 M
4662 M
7044 M
5185 M
1859 M
2861 M
429 M
3235 M
3589 M
2139 M
—
—
—
—
2218 M
28,5 mil M
19,5 %
—
—
—
§9 Comparación de valoración con pares
Valor razonableReport-date price
Medtronic plcMDT
Precio / valor razonable
Valor razonable95,89 US$Report-date price76,82 US$
Fecha de evaluación
Ventaja competitivaWide
Cuadro de mando de inversión69 / 100
Abbott LaboratoriesABT
Precio / valor razonable
Valor razonable86,74 US$Report-date price105,52 US$
Fecha de evaluación
Ventaja competitivaNone
Cuadro de mando de inversión52 / 100
Stryker CorporationSYK
Precio / valor razonable
Valor razonable313,18 US$Report-date price297,6 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión75 / 100
Medtronic plcMDT
Precio / valor razonable
Valor razonable95,89 US$Report-date price76,82 US$
Healthcare system capital spending constraints and deferred procedures delay volume recovery.
Posicionamiento
High dividend payout limits aggressive M&A, forcing reliance on internal R&D and pipeline execution.
§11 Gestión de posiciónEN
Tamaño de posición
Core holding given mature dividend archetype and low downside risk.
Riesgo
Re-evaluate if capex/revenue structurally disconnects or if forward revenue estimates drop below 1.5%.
Tramos de entrada
Nivel
Acción
Por qué
Current / pullbacks
Tramos de salida
Nivel
Acción
Thesis break
Re-evaluate if capex/revenue structurally disconnects or if forward revenue estimates drop below 1.5%.
§12 Perspectivas de inversoresEN
Bull view
Buy
Buy. The current share price fails to credit the immense durability of Medtronic's free cash flow engine, providing a large margin of safety against sluggish top-line growth.
Base view
Buy
The 1.73% implied growth hurdle from the Reverse DCF confirms extreme market pessimism. Our multi-model synthesis relies heavily on structural cash generation to bypass near-term trailing noise.
§14 Recomendación finalEN
Acción
Comprar
Buy. The current share price fails to credit the immense durability of Medtronic's free cash flow engine, providing a large margin of safety against sluggish top-line growth.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Sub-par capital efficiency indicates that elevated capital outlays are failing to produce accretive operating profits. Generating returns below the corporate hurdle rate erodes economic value and restricts capital redeployment toward high-growth medtech innovations, weakening long-term competitive differentiation.
Actual:6.6% as of 2026-05-12
Alerta siROIC declines below 5.0% over a twelve-month period
Persistent margin degradation reflects an inability to offset customer pricing pressure and medical inflation through cost containment. Compressing operating margins directly reduces free cash flow generation, eliminating bottom-line operating leverage and endangering the company's valuation multiple relative to peers.
Actual:19.5% for the period ended 2025-04-30
Alerta siOperating margin falls below 19.5% over two consecutive fiscal quarters
Escalating cash commitment to shareholder payouts leaves little cushion against revenuevolatility or unexpected clinical liabilities. Exceeding sustainable cash boundaries forces either an outright dividend reduction or debt-funded shareholder returns, destroying the core defensive income thesis and triggering severe multiple compression.
Major regulatory or clinical setbacks freeze critical product launch cycles in high-margin growth categories. Failing to refresh innovative offerings allows agile competitors to permanently capture market share, undermining premium pricing power and eliminating key anticipated drivers of mid-single-digit top-line acceleration.
Actual:Active pipeline development programs as of 2026-05-12
Alerta si1 or more formal FDA rejections or Phase 3 clinical trial terminations in Cardiovascular or Diabetes pipelines within a 12-month period
Monitor the threat against the report checkpoints.
Regulatory delays stalling product cycles.
medium
Monitor
Monitor the threat against the report checkpoints.
Warning level: ROIC declines below 5.0% over a twelve-month period. Sub-par capital efficiency indicates that elevated capital outlays are failing to produce accretive operating profits. Generating returns below the corporate hurdle rate erodes economic value and restricts capital redeployment toward high-growth medtech innovations, weakening long-term competitive differentiation.
Warning level: Dividend payout ratio exceeds 90% of free cash flow over an annual period. Escalating cash commitment to shareholder payouts leaves little cushion against revenuevolatility or unexpected clinical liabilities. Exceeding sustainable cash boundaries forces either an outright dividend reduction or debt-funded shareholder returns, destroying the core defensive income thesis and triggering severe multiple compression.
05
Métrica:
Cardiovascular and Diabetes Clinical Approvals
ActualActive pipeline development programs as of 2026-05-12
Por qué importa
Warning level: 1 or more formal FDA rejections or Phase 3 clinical trial terminations in Cardiovascular or Diabetes pipelines within a 12-month period. Major regulatory or clinical setbacks freeze critical product launch cycles in high-margin growth categories. Failing to refresh innovative offerings allows agile competitors to permanently capture market share, undermining premium pricing power and eliminating key anticipated drivers of mid-single-digit top-line acceleration.
Boston Scientific CorporationBSX
Precio / valor razonable
Valor razonable65,94 US$Report-date price44,51 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión72 / 100
Edwards Lifesciences CorporationEW
Precio / valor razonable
Valor razonable62,28 US$Report-date price85,71 US$
